SEC Form 4 · accession 0000899243-15-002556
Aegerion Pharmaceuticals, Inc. · AEGR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William T. Andrews
Officer — See Remarks
Period of report
Aug 4, 2015
Accepted (ET)
Aug 6, 2015 · 4:28 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001338042
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2,F3 | $19.52 | Aug 4, 2015 | A | 40,000 | A | — | Aug 4, 2025 | Common Stock | 40,000 | 40,000 | D |
Explanation of responses
- F1The stock option award was made to the Reporting Person as part of a retention arrangement approved by the Issuer's Board of Directors on August 4, 2015.
- F2The stock option award has an exercise price equal to the fair market value of the closing price of the Issuer on the date of the grant.
- F325% of the shares of common stock underlying this stock option award will vest on August 4, 2016. The remaining 75% of the shares of common stock underlying this stock option award will vest thereafter in equal monthly installments through August 4, 2019, subject to the Reporting Person's continued employment with the Issuer.
Remarks
Senior Vice President, Business Development